T32: Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer Research

 描述(申请人提供)：纳米技术和医学之间的接口是科学探索和创造新的和改进的诊断和治疗工具以检测、治疗、治愈和预防人类疾病的新前沿。我们建议创建一个在癌症研究纳米技术(NTCR)方面的综合博士前和博士后培训计划，该计划定位于这一接口。它基于同一地区的两个家长R25和T32培训补助金。该计划将在癌症生物学的基础研究、产业合作和癌症医学的转化研究方面建立一个独特的国家资源，包括跨学科和协同计划。该计划培养经过跨学科培训的博士后和博士后研究员，为能够深入了解癌细胞功能的技术奠定基础，而不是目前使用的有限的黑盒输入-输出技术，引入分子成像的新模式，开发新的高通量诊断工具，并设计新型药物/抗体/siRNA病毒和非病毒递送系统来治疗人类癌症。NTCR成员开发新的癌症诊断方法，根据患者的遗传和表观遗传标记以及为每个患者选择和优化的疾病表型和治疗方法，评估每个患者的预后和最佳治疗。NTCR学员根据他们的背景选择两个核心课程之一，以及癌症纳米生物技术实验室课程。他们参加期刊俱乐部和专门的年度研讨会，以及临床会议和肿瘤委员会。NTCR项目每年将招收拥有医学博士和/或博士学位且具有生物化学、物理、分子/细胞/癌症生物学或工程/物理学科背景的优秀实习生，人数稳定在2名博士后和6名博士后。NTCR研究员利用NCI指定的Sidney Kimmel综合癌症中心、路德威克癌症遗传学和治疗中心、Sol Goldman胰腺癌中心和体内细胞和分子成像中心的研究和临床资源，以及最近成立的约翰霍普金斯纳米生物技术研究所(INBT)独特的教育资源和实验设施，该研究所拥有癌症纳米技术卓越中心(CCNE)和物理科学肿瘤学中心(PSOC)。与公共卫生的相关性。拟议的博士后和博士后培训计划将培训纳米技术和癌症医学之间的研究员，以开发新的纳米级治疗、预后和诊断工具，用于检测、诊断、治疗和治愈人类癌症。

 DESCRIPTION (provided by applicant): The interface between nanotechnology and medicine is a new frontier for scientific exploration and for the creation of new and improved diagnostic and therapeutic tools to detect, treat, cure, and prevent human diseases. We propose to create an integrated predoctoral and postdoctoral training program in nanotechnology for cancer research (NTCR) that is positioned at this interface. It is based on two parent R25 and T32 training grants in the same area. This program will establish a unique national resource with interdisciplinary and synergistic programs in fundamental research in cancer biology, industrial collaboration, and translational research in cancer medicine. This program fosters predoctoral and postdoctoral fellows who are trained across disciplines to lay foundations for technologies that enable an inside-view of cancer cell functions as opposed to the limited black-box input-output techniques currently used, introduce new modalities for molecular imaging, develop new high-throughput diagnostic tools, and engineer novel drug/antibody/siRNA viral and non-viral delivery systems to treat human cancers. NTCR fellows develop novel cancer diagnostics to evaluate each individual patient's prognosis and optimal treatment, based upon the patients' genetic and epigenetic markers and disease phenotype and therapeutics that are selected and optimized for each individual patient. NTCR trainees take one of two core courses depending on their background, as well as a lab course in cancer nanobiotechnology. They participate in a journal club and a dedicated annual symposium, as well as clinical conferences and tumor boards. The NTCR program will recruit outstanding trainees every year with MD and/or PhD degrees and diverse backgrounds in either biochemistry, physics, molecular/cellular/cancer biology, or an engineering/physics discipline for a steady state number of 2 postdoctoral and 6 predoctoral fellows. NTCR fellows take advantage of research and clinical resources at the NCI-designated Sidney Kimmel Comprehensive Cancer Center, the Ludwick Center for Cancer Genetics and Therapeutics, The Sol Goldman Pancreatic Cancer Center, and the In Vivo Cellular and Molecular Imaging Center, as well as the unique educational resources and experimental facilities of the recently established Johns Hopkins Institute for NanoBioTechnology (INBT), which houses the center for cancer nanotechnology excellence (CCNE) and the physical sciences-oncology center (PSOC). Relevance to Public Health. The proposed predoctoral and postdoctoral training program will train fellows at the interface between nanotechnology and cancer medicine to develop novel nanoscale therapeutic, prognostic, and diagnostic tools for the detection, diagnosis, treatment and cure of human cancer.